Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merus N.V.

< Previous 1 2 Next >
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Tickers BHVN MRUS
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Pricing of Upsized Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.